Concepedia

Pietro Morlacchi

PM

Statistics

Publications

9

Citations

1.3K

H-Index

9

Active since

2008

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Beth Israel Deaconess Medical Center

Baylor College of Medicine

Agilent Technologies (United States)

Agilent Technologies (Australia)

Pietro Morlacchi is an author at The University of Texas MD Anderson Cancer Center specializing in life sciences, sh2 domain-mediated signaling, and molecular pharmacology.

Publications per year

2008–2025

9

Publications

9

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R. Molina, Yuting Sun, Marina Protopopova et al. · Nature Medicine · 2018 · 951 citations · Full text

, , +14

Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

Michael Soth, Kang Le, Maria Emilia Di Francesco et al. · Journal of Medicinal Chemistry · 2020 · 91 citations · Full text

, , +16

Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation

Yuting Sun, Madhavi Bandi, Timothy Lofton et al. · Cell Reports · 2019 · 67 citations · Full text

, , +17

Product Profile of PEN3: The Last Unexamined Oxidosqualene Cyclase in <i>Arabidopsis thaliana</i>

Pietro Morlacchi, William K. Wilson, Quanbo Xiong et al. · Organic Letters · 2009 · 48 citations

, , +15

Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity

Pijus K. Mandal, Pietro Morlacchi, John Knight et al. · Journal of Medicinal Chemistry · 2015 · 45 citations · Full text

, , +17

1–5 of 9